Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-AF: asundexian versus apixaban in atrial fibrillation
2023-503794-38-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 40
01
Overview
Phase 3, randomised, double-blind trial of asundexian in Atrial fibrillation (AFib) (2 arms), sponsored by Bayer. Primary endpoints: Time to first occurrence of composite of stroke or systemic embolism, Time to first occurrence of ISTH major bleeding and 1 more. Started Nov 2022; status: completed.
02
Drugs
asundexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2023-503794-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503794-38-00.